ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3177

Whole-Body MRI: A Valuable Diagnostic Tool for the Assessment of Disease Damage in Juvenile Dermatomyositis

Clara Malattia1, Agnese Beltramo1, Isabella Buffoni1, Annalisa Madeo1, Francesca Magnaguagno2, Stefania Viola1 and Alberto Martini1,3, 1Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, 2Istituto G Gaslini, UO Radiologia Pediatrica, Genoa, Italy, 3Pediatria, Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: imaging techniques, juvenile dermatomyositis and outcomes, MRI

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects IV: Imaging and Novel Clinical Interventions

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Although the prognosis of JDM has significantly improved during the past decade, some patients still experience persistent active disease, which potentially leads to irreversible damage and permanent disability. In patients with longstanding disease muscle weakness may be due to a combination of ongoing muscle inflammation, muscle atrophy, fatty replacement and steroid-induced myopathy; MRI allows to define the role of each of these components in the patients’ weakness and to overcome the limits of the clinical evaluation. The aim of this study is to estimate the frequency and distribution of muscle damage in JDM, using Whole-Body MRI (WB-MRI) and to investigate its feasibility and validity in the assessment of damage.

Methods:

WB-MRIs were obtained from 50 JDM patients (22M;28F, mean age 10.88 years, mean disease duration 3.86 years) and 50 age and sex-matched controls, using a 1.5 T MRI scanner. Muscular atrophy and fatty replacement were assessed on T1 W sequences and scored in 39 muscular groups using a 0-2 and a 0-1 point scales respectively. WB-MRI and clinical assessments were performed concurrently and the results compared. Validation procedures included analysis of reliability, construct validity and discriminative validity.

Results:

WB-MRI revealed muscle atrophy in 43/50 patients (86%) and fatty replacement in 17/50 patients (34%). Quadriceps and ileopsoas muscles were more frequently affected. The inter-reader agreement for WB-MRI scores ranged from moderate to excellent (with Cohen’s kappa ranging from 0.556-1 for the individual muscular group and intra-class correlation coefficient 0.96 for the total muscular damage score). Correlations between MDI and muscle atrophy (rs=0.4, p< 0.01) and fatty replacement (rs=0.51, p= 0.0007) were moderate and, as expected, MRI muscular damage score did not correlate with traditional measurements of disease activity. Unexpectedly, MRI damage scores did not correlate with disease duration or steroid therapy. None of controls showed signal changes in muscle revealing an excellent discriminant validity of the WB-MRI score.

WB imaging allowed to detect abnormalities in other organ and systems, including osteonecrosis   (6/50 patients, 12%), vertebral fractures (7/50, 14%) and calcinosis (14/50, 28%). Other incidental findings detected by WB MRI were a renal cyst and a thyroidal lesion which resulted to be a papillary thyroid carcinoma.

Conclusion:

WB-MRI represents a promising tool to estimate the overall spectrum of damage in JDM. An accurate discrimination between the persistent disease activity and the disease damage burden is crucial to guide treatment decision.


Disclosure: C. Malattia, None; A. Beltramo, None; I. Buffoni, None; A. Madeo, None; F. Magnaguagno, None; S. Viola, None; A. Martini, None.

To cite this abstract in AMA style:

Malattia C, Beltramo A, Buffoni I, Madeo A, Magnaguagno F, Viola S, Martini A. Whole-Body MRI: A Valuable Diagnostic Tool for the Assessment of Disease Damage in Juvenile Dermatomyositis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/whole-body-mri-a-valuable-diagnostic-tool-for-the-assessment-of-disease-damage-in-juvenile-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whole-body-mri-a-valuable-diagnostic-tool-for-the-assessment-of-disease-damage-in-juvenile-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology